Alector Inc (ALEC)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $378.15M
Last updated: Nov 17, 2026 at 11:04 AM ET
Alector Inc (ALEC) Earnings: Report Dates and Results
Alector (ALEC) is expected to report earnings on Feb 23, 2027. In the quarter ended Sep 30, 2026, Alector reported EPS of $1.11, above the -$0.23 estimate. It beat the EPS estimate in each of the last 15 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
ALEC has an expected report date of Feb 23, 2027.
ALEC Earnings Call
The latest ALEC earnings call transcript on file is labeled 2025Q2.
Read the 2025Q2 transcriptEarnings History
Of the 32 quarters below that had an estimate, ALEC beat 18, missed 12 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $162.87M, up 4896.0% from $3.26M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $1.11 | -$0.23 | -$0.24 - $1.21 | +582.61% | Beat | N/A | 5 | 1 up, 0 down | Nov 5, 2026 | $162.87M |
| Jun 30, 2026 | -$0.21 | -$0.24 | -$0.31 - -$0.18 | +12.50% | Beat | N/A | 6 | N/A | Aug 6, 2026 | $3.32M |
| Mar 31, 2026 | -$0.21 | -$0.27 | -$0.44 - $0.10 | +22.22% | Beat | N/A | 7 | 1 up, 0 down | May 7, 2026 | $1.05M |
| Dec 31, 2025 | -$0.34 | -$0.39 | -$0.50 - -$0.29 | +13.11% | Beat | N/A | 6 | 1 up, 1 down | Feb 25, 2026 | $6.24M |
| Sep 30, 2025 | -$0.34 | -$0.41 | -$0.47 - -$0.35 | +17.07% | Beat | N/A | 7 | 0 up, 1 down | Nov 6, 2025 | $3.26M |
| Jun 30, 2025 | -$0.30 | -$0.45 | -$0.54 - -$0.35 | +33.33% | Beat | N/A | 5 | 1 up, 2 down | Aug 7, 2025 | $7.87M |
| Mar 31, 2025 | -$0.41 | -$0.46 | -$0.53 - -$0.41 | +10.87% | Beat | N/A | 4 | 1 up, 2 down | May 8, 2025 | $3.67M |
| Dec 31, 2024 | -$0.02 | -$0.54 | -$0.75 - -$0.07 | +96.33% | Beat | N/A | 7 | 3 up, 1 down | Feb 26, 2025 | $54.24M |
| Sep 30, 2024 | -$0.43 | -$0.53 | -$0.59 - -$0.47 | +18.87% | Beat | N/A | 11 | 0 up, 0 down | Nov 6, 2024 | $15.34M |
| Jun 30, 2024 | -$0.40 | -$0.48 | -$0.60 - -$0.44 | +16.67% | Beat | -2100.0% | 10 | 1 up, 0 down | Aug 7, 2024 | $15.08M |
| Mar 31, 2024 | -$0.38 | -$0.49 | -$0.64 - -$0.34 | +22.45% | Beat | N/A | 9 | 0 up, 0 down | May 8, 2024 | $15.89M |
| Dec 31, 2023 | -$0.49 | -$0.77 | -$0.83 - -$0.65 | +36.36% | Beat | N/A | 11 | 2 up, 0 down | Feb 27, 2024 | $15.19M |
| Sep 30, 2023 | -$0.53 | -$0.65 | -$0.78 - -$0.51 | +18.46% | Beat | N/A | 11 | 0 up, 0 down | Nov 7, 2023 | $9.11M |
| Jun 30, 2023 | $0.02 | -$0.82 | -$0.92 - -$0.74 | +102.44% | Beat | -83.3% | 10 | 0 up, 0 down | Aug 3, 2023 | $56.21M |
| Mar 31, 2023 | -$0.55 | -$0.78 | -$0.90 - -$0.55 | +29.49% | Beat | N/A | 11 | 1 up, 1 down | May 4, 2023 | $16.55M |
| Dec 31, 2022 | -$0.63 | -$0.46 | -$0.82 - -$0.14 | -36.96% | Miss | N/A | 11 | 0 up, 0 down | Feb 28, 2023 | $14.44M |
| Sep 30, 2022 | -$0.56 | -$0.51 | -$0.80 - -$0.30 | -9.80% | Miss | -137.6% | 9 | 0 up, 0 down | Nov 8, 2022 | $14.85M |
| Jun 30, 2022 | $0.12 | -$0.44 | -$0.78 - -$0.14 | +127.27% | Beat | N/A | 11 | 0 up, 0 down | Aug 4, 2022 | $79.85M |
| Mar 31, 2022 | -$0.54 | $0.17 | -$0.60 - $1.71 | -417.65% | Miss | N/A | 10 | 0 up, 0 down | May 5, 2022 | $24.47M |
| Dec 31, 2021 | -$0.68 | -$0.19 | -$2.18 - $1.31 | -257.89% | Miss | N/A | 9 | 0 up, 0 down | Feb 24, 2022 | $13.99M |
| Sep 30, 2021 | $1.49 | $2.83 | -$0.66 - $8.24 | -47.35% | Miss | N/A | 8 | N/A | Nov 4, 2021 | $182.41M |
| Jun 30, 2021 | -$0.69 | -$0.69 | -$0.77 - -$0.61 | 0.00% | In line | N/A | 9 | N/A | Aug 3, 2021 | $6.57M |
| Mar 31, 2021 | -$0.66 | -$0.67 | -$0.90 - -$0.59 | +1.49% | Beat | N/A | 9 | N/A | May 5, 2021 | $4.11M |
| Dec 31, 2020 | -$0.66 | -$0.66 | -$0.84 - -$0.49 | 0.00% | In line | N/A | 9 | N/A | Feb 25, 2021 | $13.93M |
| Sep 30, 2020 | -$0.67 | -$0.55 | -$0.62 - -$0.48 | -21.82% | Miss | N/A | 7 | N/A | Nov 10, 2020 | N/A |
| Jun 30, 2020 | -$0.58 | -$0.50 | -$0.56 - -$0.39 | -16.00% | Miss | N/A | 8 | N/A | Aug 11, 2020 | N/A |
| Mar 31, 2020 | -$0.53 | -$0.43 | -$0.48 - -$0.26 | -23.26% | Miss | N/A | 7 | N/A | May 13, 2020 | $7.17M |
| Dec 31, 2019 | -$0.45 | -$0.44 | -$0.67 - $0.39 | -2.27% | Miss | N/A | 7 | N/A | Mar 24, 2020 | N/A |
| Sep 30, 2019 | -$0.47 | -$0.40 | -$0.44 - -$0.39 | -17.50% | Miss | N/A | 2 | N/A | Nov 12, 2019 | $2.70M |
| Jun 30, 2019 | -$0.36 | -$0.32 | -$0.35 - -$0.30 | -12.50% | Miss | N/A | 3 | N/A | Aug 12, 2019 | $6.92M |
| Mar 31, 2019 | -$0.27 | -$0.31 | -$0.37 - -$0.26 | +12.90% | Beat | N/A | 4 | N/A | May 13, 2019 | $5.61M |
| Dec 31, 2018 | -$1.48 | -$0.28 | -$0.31 - -$0.27 | -428.57% | Miss | N/A | 3 | N/A | Feb 7, 2019 | $9.14M |
| Sep 30, 2018 | -$0.29 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Oct 12, 2018 | $6.50M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.39, after -$1.23 the year before. It was -$1.77 for the year ended Dec 31, 2018, the oldest of the 8 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.39 | N/A |
| Dec 31, 2024 | -$1.23 | N/A |
| Dec 31, 2023 | -$1.55 | N/A |
| Dec 31, 2022 | -$1.61 | N/A |
| Dec 31, 2021 | -$0.54 | N/A |
| Dec 31, 2020 | -$2.44 | N/A |
| Dec 31, 2019 | -$1.55 | N/A |
| Dec 31, 2018 | -$1.77 | N/A |
Earnings Calls
The 3 most recent earnings calls are listed below; the latest, 2025Q2 for the period ended Jun 30, 2025, runs about 6,000 words across 14 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2025Q2 | Jun 30, 2025 | 5,963 | 14 | |
| 2024Q4 | Dec 31, 2024 | 5,915 | 13 | |
| 2024Q2 | Jun 30, 2024 | 6,178 | 10 |
2025Q2 Earnings Call
Opening remarks
Katie Hogan Senior Director of Corporate Communications and Investor Relations Thank you, operator, and hello, everyone. Earlier this afternoon, we released our financial results for the second quarter 2025. The press release is available on our website at www.alector.com, and our 10-Q was filed with the Securities and Exchange Commission this afternoon. Joining me on the call today are Dr. Arnon Rosenthal, Co-Founder and CEO; Dr. Sara Kenkare-Mitra, President and Head of Research and Development; Dr. Giacomo Salvadore, Chief Medical Officer; Neil Berkley, Chief Business Officer and Interim Chief Financial Officer; and guest speaker, Dr. Ryan Darby, Associate Professor of Neurology and Director of the Frontotemporal Dementia Clinic at Vanderbilt University Medical Center as well as a paid consultant to Alector, who will provide clinical context on frontotemporal dementia. After our formal remarks, we'll open the call for Q&A. I'd like to note that during this call, we'll be making a number of forward-looking statements. Please take a moment to review our slide on the webcast, which contains our forward-looking statement disclosure, and we also encourage you to review our SEC filings for more information. I would now like to turn the call over to Arnon Rosenthal, Chief Executive Officer. Arnon?
Arnon Rosenthal Co-Founder and CEO Thank you, Katie, and good afternoon, everyone. As we enter the second half of 2025, Alector is approaching an important inflection point. By mid-fourth quarter, we expect top line data from our pivotal Phase III INFRONT-3 trial of latozinemab, our most advanced clinical program. This trial represents the first rigorous test of the progranulin elevating approach to treating frontotemporal dementia due to the GRN gene mutation, a fatal and rare form of dementia that strikes people decades earlier than Alzheimer's disease and currently has no approved therapy. We designed latozinemab based on clear biological and human genetic rationale to elevate progranulin levels by blocking its internalization and degradation by the sortilin receptor. FTD-GRN is directly caused by progranulin deficiency, and restoring it has the potential to alter the course of the disease. Our earlier studies in participants with FTD-GRN provided encouraging signals, both in biomarkers and in clinical progression. INFRONT-3 will allow us to determine whether those findings hold up in a larger placebo-controlled, double-blinded trial. Together with our partner, GSK, we are advancing launch readiness activities to help ensure we are well positioned to support the potential commercialization of latozinemab. Additionally, we are also excited about our late-stage clinical program in early Alzheimer's disease, where we are advancing AL101, our second progranulin elevating antibody, which is currently in Phase II trial. There is a strong genetic and biological rationale for the role of progranulin in Alzheimer's disease.
Frequently Asked Questions About ALEC
When is Alector's next earnings date?
Alector's next earnings report is expected for Feb 23, 2027.
Did ALEC beat earnings estimates last quarter?
Yes. Alector reported EPS of $1.11 for the quarter ended Sep 30, 2026, above the -$0.23 estimate, a 582.61% surprise.
What EPS do analysts expect from ALEC next quarter?
The consensus EPS estimate for Alector for the quarter ending Dec 31, 2026 is $0.24 from 9 analysts, with estimates from -$0.27 to $0.65.
How often does ALEC beat earnings estimates?
Alector beat the EPS estimate in each of the last 15 quarters, with an average surprise of +68.85%.
ALEC pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors